Literature DB >> 14696303

Fulminant hepatic failure.

David A Sass1, A Obaid Shakil.   

Abstract

FHF is a devastating illness of varied causes, carrying considerable mortality and affecting patients with previously healthy livers. The clinical presentation varies widely but encephalopathy is the defining criterion. Management requires a multidisciplinary approach, including rapid triage, monitoring, and referral to a transplantation center for further evaluation. Early prognostication and timely availability of donor livers are essential for a successful outcome. A donor shortage, however, continues to pose problems for both hepatologists and surgeons. Effective liver support devices may greatly prolong the window of opportunity to provide a donor liver, or alternatively to allow the native liver to regenerate. Despite decades of great progress in the field of liver support systems, the ideal system is still a long-cherished goal in hepatology. Hybrid systems have garnered most of the recent attention, but the quest for improved synthetic function has not yet been realized. It is hoped that rapid conceptual and technologic developments with respect to hybrid systems, hepatocyte transplantation, and xenografting will yield a safe and accessible tool for managing these critically ill patients. Controlled, multicenter trials in well-defined patient groups and with standard outcome measures are essential to evaluate the clinical value of these devices. A better understanding of mechanisms responsible for liver cell death and multiorgan failure, and the development of strategies to enhance liver regeneration, may allow a more targeted approach to therapy.

Entities:  

Mesh:

Year:  2003        PMID: 14696303     DOI: 10.1016/s0889-8553(03)00088-8

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  6 in total

1.  Combined human growth hormone and lactulose for prevention and treatment of multiple organ dysfunction in patients with severe chronic hepatitis B.

Authors:  Hui-Guo Ding; Jing Shan; Bin Zhang; Hong-Bo Ma; Li Zhou; Rui Jin; Yu-Fen Tan; Li-Xiang He
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

2.  Acute Liver Failure.

Authors:  J Eileen Hay
Journal:  Curr Treat Options Gastroenterol       Date:  2004-12

3.  Proliferation of L02 human hepatocytes in tolerized genetically immunocompetent rats.

Authors:  Hu Lin; Qing Mao; Yu-Ming Wang; Li Jiang
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

4.  Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.

Authors:  Gadi Lalazar; Tomer Adar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

5.  Exogenous adenosine 5'-triphosphate does not improve survival in rats with acute liver failure.

Authors:  Erin P Becker; DongFeng Sun; Gerald Y Minuk
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 6.  Global distribution of infectious diseases requiring intensive care.

Authors:  Raul E Istúriz; Jaime Torres; José Besso
Journal:  Crit Care Clin       Date:  2006-07       Impact factor: 3.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.